Know Cancer

forgot password

Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours

Phase 1
18 Years
Open (Enrolling)
Malignant Solid Tumour

Thank you

Trial Information

Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours

CGTG-102 is an adenovirus that has been armed with granulocyte-macrophage colony stimulating
factor (GMCSF), a potent stimulator of immunological cells.

With regard to oncolytic viruses, replication in normal cells does not take place, and
therefore viruses such as CGTG-102 are not known to cause any disease. Further, to date
there has been no incidence of passing the virus on to other humans from patients. Since the
virus requires tumor cells to multiply, such events are unlikely.

To this day more than 100 patients have been treated with CGTG-102. This clinical trial will
take place over approximately 6 months. The study includes 12 visits to the hospital, 1
screening visit, 9 injection visits including overnight stay at the hospital(performed on
trial days 1, 4, 8, 15, 29, 57, 85, 113 and 141), 1 end of treatment visit (day 169) and 1
end of study visit (day 190). Oral treatment with cyclophosphamide (1 pill per day) will
start on the day after the first injection and last until visit day 169.

Inclusion Criteria:

1. Solid tumour refractory to evidence-based oncological therapies.

2. Age 18 years and over.

3. At least one tumour mass measurable by PET (i.e. PET-positive lesion that can
reliably be assessed for SUVmax, typically featuring longest diameter ≥2 cm).

4. Tumour is injectable i.t. by direct visualisation/palpation or by imaging-guidance
(ultrasound). I.t. includes intracavitary injections, particularly intraperitoneal
and intrapleural.

5. Histological confirmation of primary disease or relapse.

6. Patient has given signed informed consent.

7. WHO performance score 0-1 and life expectancy more than 3 months.

8. Previous anti-cancer treatment at least 1 month before Day 1.

9. Tumour assessed to be suitable for biopsy.

10. Hepatic, renal and bone marrow functions within normal limits for the target
population as indicated by the following:

- Total bilirubin ≤ the upper limit of normal (ULN).

- ASAT, ALAT ≤3.0 × ULN.

- Serum creatinine ≤1.5 x ULN.

- International normalised ratio (INR) ≤1.5 x ULN.

- Haematologic parameters: Patients can be transfused to meet the haemoglobin and
platelet count entry criteria.

- Haemoglobin ≥10 g/dL

- Leucocytes ≥2.3 x 109/L

- Platelet count ≥7.5 x 109/L

Exclusion Criteria:

1. Use of high dose systemic immune suppressive medication within 3 weeks of anticipated
first treatment. Note: patients taking low-dose corticosteroids for the treatment of
nausea and/or taking maintenance corticosteroids are permitted to enrol.

2. Known infection with HIV or known underlying genetic immunodeficiency disease as
these might affect the safety and efficacy of treatment.

3. Treatment of the injected tumour(s) with radiotherapy, chemotherapy, surgery, or an
investigational drug within 4 weeks prior to the first treatment.

4. Recent thromboembolic event (deep venous thrombosis, pulmonary embolism).

5. Clinically significant active infection or clinically significant medical condition
considered high risk for investigational new drug treatment (e.g. pulmonary,
neurological, cardiovascular, metabolic, clinically significant and/or rapidly
accumulating pericardial effusion).

6. Severe or unstable cardiac disease.

7. Known brain metastases, glioma. Central nervous system malignancy, including
carcinomatosis meningitis.

8. Pulse oximetry oxygen saturation <90% at rest in room air.

9. Vaccination with a live virus (i.e. measles, mumps, rubella, etc.) <30 days prior to
the first treatment.

10. History of hepatic dysfunction, cirrhosis or hepatitis.

11. Prior organ transplant.

12. Pregnant or lactating patients.

13. Evidence of coagulation disorder.

14. Other conditions which, in the opinion of the investigator, might interfere with the
study findings or represent a safety hazard for the patient.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the recommended phase II dose.

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Mikael von Euler, MD PhD

Investigator Role:

Study Director

Investigator Affiliation:

Oncos Therapeutics Ltd.


Finland: Finnish Medicines Agency

Study ID:




Start Date:

April 2012

Completion Date:

April 2013

Related Keywords:

  • Malignant Solid Tumour
  • Phase I
  • Dose escalation
  • oncolytic virus
  • Neoplasms